Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,957.50p on 23-03-2026 at 15:10:48
Change 7.00p 0.36%
Buy 1,958.00p
Sell 1,957.00p
Last Trade: Sell 98.00 at 1,957.00p
Day's Volume: 6,009,039
Last Close: 1,950.50p
Open: 1,926.00p
ISIN: GB00BN7SWP63
Day's Range 1,906.50p - 1,966.50p
52wk Range: 1,242.50p - 2,282.00p
Market Capitalisation: £78.34b
VWAP: 1,936.67177p
Shares in Issue: 4.00b

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 98 1,957.00p Automatic Execution
15:10:43 - 23-Mar-26
Sell* 82 1,957.00p Automatic Execution
15:10:43 - 23-Mar-26
Sell* 202 1,957.00p Automatic Execution
15:10:43 - 23-Mar-26
Buy* 77 1,957.50p SI Trade
15:10:38 - 23-Mar-26
Sell* 2,776 1,957.00p SI Trade
15:10:38 - 23-Mar-26
Sell* 100 1,957.00p Automatic Execution
15:10:38 - 23-Mar-26
Buy* 320 1,957.50p Automatic Execution
15:10:36 - 23-Mar-26
Buy* 100 1,957.50p Automatic Execution
15:10:36 - 23-Mar-26
Buy* 687 1,957.00p Automatic Execution
15:10:36 - 23-Mar-26
Buy* 422 1,957.00p Automatic Execution
15:10:36 - 23-Mar-26
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
23rd Mar 2026 (Mon) 1,926.00 1,966.50 1,906.50 1,950.50 6,009,039
20th Mar 2026 (Fri) 1,960.00 1,967.50 1,940.50 1,950.50 14,988,054
19th Mar 2026 (Thu) 1,951.50 1,976.00 1,943.50 1,956.00 7,174,578
18th Mar 2026 (Wed) 2,010.00 2,013.00 1,945.50 1,972.50 8,290,930
17th Mar 2026 (Tue) 2,032.00 2,037.00 2,002.00 2,013.00 11,964,583
16th Mar 2026 (Mon) 2,037.00 2,053.00 2,026.00 2,026.00 6,815,220
13th Mar 2026 (Fri) 2,029.00 2,062.00 2,027.00 2,031.00 8,608,847
12th Mar 2026 (Thu) 2,053.00 2,057.00 2,015.00 2,031.00 7,904,164
11th Mar 2026 (Wed) 2,063.00 2,077.00 2,046.00 2,066.00 4,932,959
10th Mar 2026 (Tue) 2,067.00 2,085.00 2,052.00 2,064.00 9,406,603
9th Mar 2026 (Mon) 1,994.00 2,051.00 1,987.50 2,046.00 9,595,185
6th Mar 2026 (Fri) 2,080.00 2,080.00 2,028.00 2,038.00 5,641,142
5th Mar 2026 (Thu) 2,114.00 2,135.00 2,072.00 2,076.00 8,766,502
4th Mar 2026 (Wed) 2,125.00 2,149.00 2,110.00 2,115.00 6,322,356
3rd Mar 2026 (Tue) 2,165.00 2,171.00 2,115.00 2,122.00 6,689,092
2nd Mar 2026 (Mon) 2,194.00 2,196.00 2,168.00 2,180.00 6,965,200
27th Feb 2026 (Fri) 2,166.00 2,201.00 2,153.00 2,201.00 14,107,273
26th Feb 2026 (Thu) 2,196.00 2,211.00 2,154.00 2,167.00 7,370,581
25th Feb 2026 (Wed) 2,182.00 2,217.00 2,176.00 2,214.00 11,628,452
24th Feb 2026 (Tue) 2,194.00 2,218.00 2,176.00 2,201.00 6,378,038
23rd Feb 2026 (Mon) 2,206.00 2,214.00 2,183.00 2,206.00 6,741,406
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
20th Mar 2026 7:00 am RNS Transaction in Own Shares
19th Mar 2026 12:00 pm RNS Lynavoy (linerixibat) approved by US FDA
19th Mar 2026 7:00 am RNS Transaction in Own Shares
18th Mar 2026 3:30 pm RNS Director/PDMR Shareholding
18th Mar 2026 7:00 am RNS Transaction in Own Shares
17th Mar 2026 3:30 pm RNS Director/PDMR Shareholding
17th Mar 2026 7:00 am RNS Transaction in Own Shares
17th Mar 2026 7:00 am RNS Transaction in Own Shares
16th Mar 2026 7:00 am RNS Transaction in Own Shares
16th Mar 2026 7:00 am RNS Transaction in Own Shares
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

GSK's lung cancer treatment secures "orphan drug" status in Japan

23rd Mar 2026 08:37

(Alliance News) - GSK PLC on Monday said Japanese health authorities had granted "orphan drug" status to its lung cancer treatment. Read More

LONDON BRIEFING: GSK gains Japan nod; Anglo to delist shares in Zurich

23rd Mar 2026 07:59

(Alliance News) - GSK makes regulatory progress in Japan for a cancer therapy, Anglo American moves to delist from the Swiss exchange as part of its restructuring, and Applied Nutrition reports strong interim growth while holding back on shareholder payouts. Read More

GSK hails US FDA approval of Lynavoy for cholestatic pruritis form

19th Mar 2026 12:20

(Alliance News) - GSK PLC on Thursday said the US Food & Drug Administration approved Lynavoy for the treatment of cholestatic pruritus in patients with primary biliary cholangitis. Read More

UK shareholder meetings calendar - next 7 days

18th Mar 2026 11:43

Read More

LONDON MARKET CLOSE: Stocks and pound rise; US rate call approaches

17th Mar 2026 17:05

(Alliance News) - Stock prices in London closed higher on Tuesday, as uncertainty surrounding the Middle East conflict continued. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value10,027.41
Change109.08

Login to your account

Forgot Password?

Not Registered